Marvel Biosciences Corp. announced a non-brokered private placement offering of 10 to 20 million units at $0.15 each, aiming to raise $1.5 to $3 million. Each unit includes one common share and one warrant to buy an additional share at $0.20, exercisable after 61 days for one year, with potential accelerated expiry. The funds will support phase 1 clinical trials for their lead compound MB-204, administrative costs, and working capital. The offering is subject to regulatory approvals and expected to close starting September 30, 2026.
Marvel Biosciences update is the subject, with Pluang data offering market context. For readers following health-sector stocks, 60 of 91 US stocks rose and 30 fell today. Notable movers include Illumina at USD 244.29 with a 6.71% increase and 100% buy order activity, Enveric Biosciences at USD 1.59 up 6.71%, and Sana Biotechnology at USD 3.10 up 6.34%. Data is as of Sep 18, 2026 03:42 WIB.
Jefferies maintained a Hold rating on Kinder Morgan, lowering its price target from $35 to $33, which remains above the current stock price of $31.31. The company benefits from stable cash flows, with 96% secured by fee-based or hedged contracts, inc...
Several stocks saw sharp gains driven by key company developments. bioAffinity Technologies surged 63.55% after securing a Hong Kong patent for its lung cancer diagnostic technology, boosting its Asian market position. Antelope Enterprise Holdings ro...
KB Home is set to report its Q3 2026 earnings on September 22, with analysts projecting a 45.3% drop in earnings per share to around $0.89 and a 20.2% decline in revenue to about $1.30 billion compared to last year. The consensus EPS estimate has rec...
An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...
Zcash (ZEC) price jumped above $1,400 following a strong rally driven by a nearly unanimous vote to reduce block times from 75 to 25 seconds in the NU7 upgrade. Institutional interest grew as Paradigm co-founder Matt Huang disclosed the firm's ZEC ho...
